175 related articles for article (PubMed ID: 38243078)
21. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
[TBL] [Abstract][Full Text] [Related]
22. RAC1 as a Therapeutic Target in Malignant Melanoma.
Cannon AC; Uribe-Alvarez C; Chernoff J
Trends Cancer; 2020 Jun; 6(6):478-488. PubMed ID: 32460002
[TBL] [Abstract][Full Text] [Related]
23. CSN6 promotes melanoma proliferation and metastasis by controlling the UBR5-mediated ubiquitination and degradation of CDK9.
Zhang Y; Hou J; Shi S; Du J; Liu Y; Huang P; Li Q; Liu L; Hu H; Ji Y; Guo L; Shi Y; Liu Y; Cui H
Cell Death Dis; 2021 Jan; 12(1):118. PubMed ID: 33483464
[TBL] [Abstract][Full Text] [Related]
24. Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma.
Martins Nascentes Melo L; Herrera-Rios D; Hinze D; Löffek S; Oezel I; Turiello R; Klein J; Leonardelli S; Westedt IV; Al-Matary Y; Egea-Rodriguez S; Brenzel A; Bau M; Sucker A; Hadaschik E; Wirsdörfer F; Hanenberg H; Uhlenbrock N; Rauh D; Poźniak J; Rambow F; Marine JC; Effern M; Glodde N; Schadendorf D; Jablonska J; Hölzel M; Helfrich I
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37028818
[TBL] [Abstract][Full Text] [Related]
25. Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma.
Yu J; Yan J; Guo Q; Chi Z; Tang B; Zheng B; Yu J; Yin T; Cheng Z; Wu X; Yu H; Dai J; Sheng X; Si L; Cui C; Bai X; Mao L; Lian B; Wang X; Yan X; Li S; Zhou L; Flaherty KT; Guo J; Kong Y
Clin Cancer Res; 2019 Nov; 25(21):6511-6523. PubMed ID: 31375512
[TBL] [Abstract][Full Text] [Related]
26. FMRP ligand circZNF609 destabilizes RAC1 mRNA to reduce metastasis in acral melanoma and cutaneous melanoma.
Shang Q; Du H; Wu X; Guo Q; Zhang F; Gong Z; Jiao T; Guo J; Kong Y
J Exp Clin Cancer Res; 2022 May; 41(1):170. PubMed ID: 35534866
[TBL] [Abstract][Full Text] [Related]
27. RAC1 GTPase plays an important role in γ-irradiation induced G2/M checkpoint activation.
Yan Y; Greer PM; Cao PT; Kolb RH; Cowan KH
Breast Cancer Res; 2012 Apr; 14(2):R60. PubMed ID: 22494620
[TBL] [Abstract][Full Text] [Related]
28. Oncogenic mutations on Rac1 affect global intrinsic dynamics underlying GTP and PAK1 binding.
Acuner SE; Sumbul F; Torun H; Haliloglu T
Biophys J; 2021 Mar; 120(5):866-876. PubMed ID: 33515600
[TBL] [Abstract][Full Text] [Related]
29. Bioinformatic analysis of RHO family of GTPases identifies RAC1 pharmacological inhibition as a new therapeutic strategy for hepatocellular carcinoma.
Bayo J; Fiore EJ; Dominguez LM; Cantero MJ; Ciarlantini MS; Malvicini M; Atorrasagasti C; Garcia MG; Rossi M; Cavasotto C; Martinez E; Comin J; Mazzolini GD
Gut; 2021 Jul; 70(7):1362-1374. PubMed ID: 33106353
[TBL] [Abstract][Full Text] [Related]
30. Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma.
Colebatch AJ; Paver EC; Vergara IA; Thompson JF; Long GV; Wilmott JS; Scolyer RA
Pathology; 2022 Aug; 54(5):533-540. PubMed ID: 35248370
[TBL] [Abstract][Full Text] [Related]
31. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.
Wu X; Li J; Zhu M; Fletcher JA; Hodi FS
Mol Cancer Ther; 2012 Sep; 11(9):1905-14. PubMed ID: 22653968
[TBL] [Abstract][Full Text] [Related]
32. CDK9 inhibition activates innate immune response through viral mimicry.
Yalala S; Gondane A; Poulose N; Liang J; Mills IG; Itkonen HM
FASEB J; 2024 Apr; 38(8):e23628. PubMed ID: 38661032
[TBL] [Abstract][Full Text] [Related]
33. The RAC1 Target NCKAP1 Plays a Crucial Role in the Progression of Braf;Pten-Driven Melanoma in Mice.
Swaminathan K; Campbell A; Papalazarou V; Jaber-Hijazi F; Nixon C; McGhee E; Strathdee D; Sansom OJ; Machesky LM
J Invest Dermatol; 2021 Mar; 141(3):628-637.e15. PubMed ID: 32777214
[TBL] [Abstract][Full Text] [Related]
34. A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma.
Emran AA; Tseng HY; Gunatilake D; Cook SJ; Ahmed F; Wang S; Hersey P; Gallagher SJ; Tiffen JC
J Invest Dermatol; 2021 Sep; 141(9):2238-2249.e12. PubMed ID: 33781756
[TBL] [Abstract][Full Text] [Related]
35. Long noncoding RNA LCAT1 functions as a ceRNA to regulate RAC1 function by sponging miR-4715-5p in lung cancer.
Yang J; Qiu Q; Qian X; Yi J; Jiao Y; Yu M; Li X; Li J; Mi C; Zhang J; Lu B; Chen E; Liu P; Lu Y
Mol Cancer; 2019 Nov; 18(1):171. PubMed ID: 31779616
[TBL] [Abstract][Full Text] [Related]
36. Understanding cancer drug resistance with
Zhu EY; Schillo JL; Murray SD; Riordan JD; Dupuy AJ
iScience; 2023 Oct; 26(10):107805. PubMed ID: 37860756
[TBL] [Abstract][Full Text] [Related]
37. Targeted deletion of CD244 on monocytes promotes differentiation into anti-tumorigenic macrophages and potentiates PD-L1 blockade in melanoma.
Kim J; Kim TJ; Chae S; Ha H; Park Y; Park S; Yoon CJ; Lim SA; Lee H; Kim J; Kim J; Im K; Lee K; Kim J; Kim D; Lee E; Shin MH; Park SI; Rhee I; Jung K; Lee J; Lee KH; Hwang D; Lee KM
Mol Cancer; 2024 Feb; 23(1):45. PubMed ID: 38424542
[TBL] [Abstract][Full Text] [Related]
38. Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity.
Phadke MS; Chen Z; Li J; Mohamed E; Davies MA; Smalley I; Duckett DR; Palve V; Czerniecki BJ; Forsyth PA; Noyes D; Adeegbe DO; Eroglu Z; Nguyen KT; Tsai KY; Rix U; Burd CE; Chen YA; Rodriguez PC; Smalley KSM
Cancer Immunol Res; 2021 May; 9(5):554-567. PubMed ID: 33653716
[TBL] [Abstract][Full Text] [Related]
39. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.
Long GV; Fung C; Menzies AM; Pupo GM; Carlino MS; Hyman J; Shahheydari H; Tembe V; Thompson JF; Saw RP; Howle J; Hayward NK; Johansson P; Scolyer RA; Kefford RF; Rizos H
Nat Commun; 2014 Dec; 5():5694. PubMed ID: 25452114
[TBL] [Abstract][Full Text] [Related]
40. Targeting regulation of cyclin dependent kinase 9 as a novel therapeutic strategy in synovial sarcoma.
Li X; Seebacher NA; Xiao T; Hornicek FJ; Duan Z
J Orthop Res; 2019 Feb; 37(2):510-521. PubMed ID: 30488489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
